Improved Formulations to Enhance Bio-availability for Antisense Therapeutics

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: HDTRA1-10-P-0041
Agency Tracking Number: C101-102-0079
Amount: $70,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solicitation Year: 2010
Solicitation Topic Code: CBD10-102
Solicitation Number: 2010.1
Small Business Information
LNK Chemsolutions, LLC
4701 Innovation Drive, Lincoln, NE, 68521
DUNS: 131068186
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: Y
Principal Investigator
 Luis Nunez
 Chief Technology Officers
 (630) 854-8173
Business Contact
 Gus Larsen
Title: CEO
Phone: (402) 416-1811
Research Institution
In general, many biological and chemical agents affect the lungs directly or indirectly, even if the respiratory system is not the primary target organ of a military or terrorist attack. Both in the case of military and civilian attacks the lung can be one of the first organs affected by a chemical or biological agent. LNK Chemsolutions (LNK) with expertise in nanoparticle formulations and the University of Illinois Chicago with expertise in Acute Lung Injury (ALI) molecular biology and treatment modality development have teamed up to develop novel oral and inhalation formulation of targeted nanoparticles (NPs) containing siRNA and/or miRNA to improve the treatment of ALI unobtainable with current delivery systems.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government